ClinicalTrials.gg
RecruitingNCT07051720AKA-ReportsUpdated Jul 4, 2025

Head-to-Head Comparison of Five Enhanced Depth of Focus IOLs and One Monofocal IOL

An interventional study of Bilateral implantation of CT ASPHINA 409M and Bilateral implantation of TECNIS Eyhance ICB00 in Cataract and IOL Surgery, IOL Implantation and Presbyopia Correction, sponsored by Augenklinik Ahaus G + H GmbH & Co. KG. Recruiting at 1 site in Germany. Open to participants aged 22 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-07-04.

Sponsored by Augenklinik Ahaus G + H GmbH & Co. KG · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Registered 3 years 2 months after the study started (first participant enrolled Apr 2022, registered Jun 2025).
  • Started Apr 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Non-randomized
Ages
22 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Cataract with a site in Germany — 8 open to participants now, 11 under way, none of them phase 3. Cataract · Germany.

Planned enrollment
10th of 50
180 · median 95
Started
2022
with 2 others
No phase
35 of 61
6 open now
Primary completion
2025-10
later than 3 of 10 live
Registered
59th of 61
by date

Among the 61 studies in Cataract with a site in Germany, this one is the 10th largest by planned enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2022, is one of 35 with no phase, reaches primary completion later than 3 of the 10 other live ones, and was the 59th registered.

Cataract

1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.

Browse Cataract studies →

Open to participants now

8 of the 61 studies in Cataract with a site in Germany are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 22 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Cataract with a site in Germany, or all of them as a file.
02

Study summary

Study Goal

The goal of this clinical trial is to compare how well four different types of artificial lenses (called intraocular lenses or IOLs) help people see after cataract surgery. The main questions it aims to answer are:

Which lens gives the best vision at different distances (far, middle, and close)? How satisfied are patients with their vision after surgery? How often do patients still need glasses after surgery?

Who Can Participate Adults aged 22 to 85 years who need cataract surgery in both eyes and meet specific health requirements.

Study Design

Researchers compared six different lens types:

TECNIS Eyhance - designed to improve middle-distance vision AcrySof IQ Vivity - extends the range of clear vision LuxSmart - uses special optics for better depth of focus Rayner EMV - uses gradual light-bending technology for smooth vision transition Eycryl SERT - modifies light focus to extend clear vision range CT ASPHINA 409M - standard single-focus lens (comparison group)

Participants chose their preferred lens type after learning about each option's benefits and limitations.

What Participants Do? Participants will:

Have cataract surgery on both eyes (1-2 weeks apart) Complete vision tests at multiple distances Take contrast sensitivity tests under different lighting conditions Fill out questionnaires about vision quality and daily activities Attend follow-up visits at 1 day, 1 week, 1 month, and 3 months

This study helps patients and doctors make informed decisions about which type of artificial lens might work best for individual needs and lifestyle.

Read the detailed description

Study Rationale and Clinical Significance The increasing demand for spectacle independence following cataract surgery has driven the development of advanced intraocular lens (IOL) technologies that extend beyond traditional monofocal designs. This prospective comparative study addresses a critical gap in understanding the real-world performance of contemporary extended depth-of-focus (EDOF) IOLs versus premium monofocal lenses.

Intermediate Vision Focus: Modern lifestyle demands have elevated the importance of intermediate visual function, particularly for distances between 60-80 cm, which encompass critical daily activities including computer work, dashboard viewing, kitchen tasks, and tablet reading. Traditional monofocal IOLs inherently limit functional vision to a single focal distance, necessitating spectacle dependence for intermediate and near visual tasks. This study specifically evaluates how different optical approaches address this intermediate vision gap.

EDOF Technology Principles: The study examines five distinct optical strategies for extending depth of focus: wavefront-shaping technology (AcrySof IQ Vivity), progressive power profiles (TECNIS Eyhance), refractive aberration manipulation (LuxSmart), continuous transition diffractive optics (Rayner EMV), and spherical aberration modulation (Eycryl SERT). Each represents a different approach to creating an elongated focal point rather than discrete foci, theoretically providing enhanced intermediate performance while minimizing visual disturbances associated with multifocal designs.

Study Design and Methodology Design Framework: This prospective, single-center, comparative clinical trial employs a patient-preference methodology rather than traditional randomization. This approach reflects real-world clinical practice where IOL selection involves shared decision-making between surgeon and patient based on individual visual needs, lifestyle requirements, and risk tolerance.

Patient-Preference Rationale: The patient-preference design was selected to: (1) respect patient autonomy in premium IOL selection, (2) minimize ethical concerns associated with randomizing patients to potentially suboptimal treatments based on individual needs, and (3) generate clinically relevant real-world evidence regarding patient-chosen outcomes and satisfaction levels.

Surgical Standardization: All procedures are performed by a single experienced surgeon using standardized phacoemulsification technique with identical surgical parameters: 2.5mm superior corneal incision, 5.5mm continuous curvilinear capsulorhexis, horizontal chop phacoemulsification, and bilateral same-model IOL implantation. Target refraction aims for emmetropia with slight myopic bias.

Primary Assessment Domains Intermediate Visual Performance Distance-Specific Testing: The protocol emphasizes comprehensive intermediate visual assessment at two critical distances: 80cm and 60cm. These distances represent distinct functional zones - 80cm corresponds to automobile dashboard and extended arm's length tasks, while 60cm represents standard computer monitor and kitchen counter distances.

Measurement Methodology: Both uncorrected intermediate visual acuity (UIVA) and distance-corrected intermediate visual acuity (DCIVA) are assessed monocularly and binocularly under standardized photopic conditions (85 cd/m²) using high-contrast charts. Multiple chart sets prevent memorization effects across repeated assessments.

Clinical Significance Threshold: The study is powered to detect clinically meaningful differences of 0.1 logMAR in DCIVA, representing approximately one line of visual acuity improvement that translates to functional benefits for intermediate tasks.

Defocus Curve Analysis Defocus curve: Binocular defocus curve testing employs defocus lenses from +1.50D to -2.50D in randomized order, corresponding to simulated viewing distances from infinity to 40cm.

Depth of Focus Quantification: Two threshold levels (0.1 and 0.2 logMAR) define depth of focus as the dioptric range from 0.00D defocus to the largest negative defocus value maintaining threshold visual acuity. This methodology provides standardized assessment of extended focal range capabilities across IOL technologies.

Functional Vision Range: The defocus curve demonstrates each IOL's usable vision range, identifying optimal performance zones and transition points where visual quality degrades.

Contrast Sensitivity Assessment Multi-Condition Testing: Contrast sensitivity evaluation employs the Functional Vision Analyzer across five spatial frequencies (1.5, 3.0, 6.0, 12.0, and 18.0 cycles per degree) under three standardized lighting conditions: photopic (85 cd/m²), mesopic (3.0 cd/m²), and mesopic-with-glare (3.0 cd/m² background with 28 lux glare source).

Real-World Simulation: The three testing conditions simulate actual visual environments: photopic represents daylight conditions, mesopic simulates twilight or indoor lighting, and mesopic-with-glare replicates challenging scenarios such as night driving with oncoming headlights.

Patient-Reported Outcomes

Validated Questionnaires: Two established instruments assess subjective visual experience:

Visual Function Index-14 (VF-14): Evaluates functional visual performance across 14 daily activities including reading, driving, recognizing faces, and performing fine tasks. Each item scores 0-4 with responses weighted by individual importance, generating a 0-100 scale where higher scores indicate better visual function.

McAlinden's Quality of Vision: Assesses patient-reported visual symptoms including glare, halos, starbursts, hazy vision, distortion, and focusing difficulties. Three Rasch-tested scales measure symptom frequency, severity, and bothersome impact on daily activities.

Spectacle Independence Assessment: Comprehensive evaluation of spectacle dependence across distance, intermediate, and near tasks, with particular emphasis on complete spectacle independence rates and task-specific visual function.

Statistical Methodology Sample Size Calculation: Power analysis targets detection of 0.1 logMAR differences in DCIVA with 90% power and α=0.05, accounting for 10% attrition, requiring 200 eyes (25 patients per group).

Analysis Approach: Generalized linear modeling with inverse Gaussian regression and identity link accommodates logMAR data characteristics.

Multiple Comparison Control: Sequential Bonferroni correction controls Type I error while maintaining statistical power, with the monofocal CT ASPHINA 409M serving as the reference comparator for all pairwise analyses.

Clinical Assessment Timeline Preoperative Evaluation: Comprehensive baseline assessment includes biometry, corneal tomography, specular microscopy, optical coherence tomography, and complete ophthalmologic examination to ensure optimal surgical candidacy and establish baseline parameters.

Postoperative Follow-up: Standardized assessments at 1 day, 1 week, 1 month, and 3 months postoperatively. Primary endpoints are assessed at 1 and 3 months to capture visual stabilization and adaptation effects.

Safety Monitoring: Continuous assessment of IOL stability, posterior capsule opacification development, and complication rates throughout the follow-up period.

Innovation and Clinical Impact This protocol represents the first comprehensive head-to-head comparison of four contemporary IOL technologies using standardized methodology and validated outcome measures. The emphasis on intermediate visual performance, quantitative depth of focus analysis, multi-condition contrast sensitivity assessment, and patient-reported outcomes provides clinically relevant data for evidence-based IOL selection and patient counseling in modern cataract surgery practice.

03

Conditions studied

  • Cataract and IOL Surgery
  • IOL Implantation
  • Presbyopia Correction
  • Extended Depth of Focus

Keywords

  • Cataract surgery
  • Extended depth-of-focus
  • EDOF
  • Intraocular lens
  • Presbyopia correction
  • Spectacle independence
  • Visual outcomes
  • Patient satisfaction
  • TECNIS Eyhance
  • AcrySof IQ Vivity
  • LuxSmart
  • CT Asphina
  • RayOne EMV
  • Eyecryl SERT
04

Who can participate

Ages eligible
22 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Bilateral implantation of the same intraocular lens (IOL) model
  • Expected postoperative best-corrected distance visual acuity (BCDVA) of 0.8 (decimal) or better
  • Regular corneal astigmatism less than 1 diopter

Exclusion criteria

Exclusion Criteria:

  • Endothelial cell density \< 2,000 cells/mm²
  • Required IOL power for emmetropia falls outside the available range of +10.0 D to +30.0 D
  • Pupillary abnormalities
  • Intraocular inflammation
  • Recent ocular trauma or ocular surgery that is unresolved/unstable, or which may impair visual outcomes or increase patient risk
  • History of corneal refractive surgery (e.g., LASIK, LASEK, PRK)
  • Irregular astigmatism, as well as corneal abnormalities or opacities
  • Conditions associated with an increased risk of zonular rupture, including capsular or zonular anomalies that may lead to IOL decentration or tilt, such as pseudoexfoliation syndrome, trauma, Marfan syndrome, among others
  • Systemic or ocular diseases, or medications, that may impair vision, increase surgical risk, or confound study outcomes
  • dry eye disease affecting visual function
  • Anticipated need for retinal laser treatment or any other ocular surgical intervention during the study period
  • Pregnancy, planned pregnancy, breastfeeding, or any condition associated with hormonal fluctuations that may induce refractive changes
  • Continuous contact lens wear within the past 4 weeks
  • Inability to understand and/or complete study questionnaires
  • Advanced glaucoma with visual field defects
  • Age-related macular degeneration (exudative or geographic form)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    CT ASPHINA 409M IOL group

    The monofocal intraocular lens CT ASPHINA 409M (Carl Zeiss Meditec AG, Germany) will be implanted during catarct surgery

    Device: Bilateral implantation of CT ASPHINA 409M

  • Experimental
    TECNIS Eyhance ICB00 IOL group

    The intraocular lens TECNIS Eyhance ICB00 (Johnson \& Johnson Surgical Vision, Irvine, CA, USA) will be implanted during catarct surgery

    Device: Bilateral implantation of TECNIS Eyhance ICB00

  • Experimental
    AcrySof® IQ Vivity® IOL group

    The intraocular lens AcrySof® IQ Vivity® (Alcon Laboratories, Fort Worth, TX, USA) will be implanted during catarct surgery

    Device: Bilateral implantation of AcrySof® IQ Vivity®

  • Experimental
    LuxSmart™ IOL group

    The intraocular lens LuxSmart™ (Bausch+Lomb, Rochester, NY, USA) will be implanted during catarct surgery

    Device: Bilateral implantation of LuxSmart™

  • Experimental
    Eyecryl SERT IOL group

    The intraocular lens Eyecryl SERT (Biotech Healthcare Group, Luzern, Switzerland) will be implanted during catarct surgery

    Device: Bilateral implantation of Eyecryl SERT

  • Experimental
    RayOne EMV IOL group

    The intraocular lens RayOne EMV (Rayner Intraocular Lenses Ltd.) will be implanted during catarct surgery

    Device: Bilateral implantation of RayOne EMV

Interventions

  • DeviceBilateral implantation of CT ASPHINA 409M

    Patients will be implanted with CT ASPHINA 409M during catarct surgery. The CT Asphina 409M has been commercially available for several years and is widely used in clinical practice. Designed with aberration-neutral optical properties, it could improve contrast sensitivity and visual quality. This monofocal aspheric IOL features four-point plate haptics and a one-piece design made from hydrophilic acrylic material with hydrophobic surface properties. It also has an overall diameter of 11 mm and a 6 mm optical diameter. The lens has a sharp posterior optic edge to minimize posterior capsule opacification. It is ideally suited as a comparative referent lens to new EDOF IOLs.

  • DeviceBilateral implantation of TECNIS Eyhance ICB00

    Patients will be implanted with TECNIS Eyhance ICB00 during catarct surgery. TECNIS Eyhance ICB00 is a one-piece, posterior chamber lens with an overall diameter of 13.0 mm and an optic diameter of 6.0 mm. The lens has a spherical posterior surface and a modified aspheric anterior surface that offers a smooth and continuous change in power from the periphery to the center of the lens, without a demarcation zone.

  • DeviceBilateral implantation of AcrySof® IQ Vivity®

    Patients will be implanted with AcrySof® IQ Vivity® during catarct surgery. The AcrySof® IQ Vivity® is a single-piece, hydrophobic acrylic IOL that utilizes non-diffractive wavefront-shaping technology (X-wave™) on its anterior surface to achieve an extended range of vision. Its aspheric anterior surface features a 2.2 mm central zone composed of two smooth transition elements: the first forms a slightly elevated plateau (\~1 µm) that stretches the wavefront, while the second shifts the wavefront to create a negative extended focal range. Together, these elements could create advanced and delayed wavefronts resulting in a continuous extended focal range instead of multiple focal points, while optimizing light transmission. This UV-absorbing and blue light filtering foldable IOL has a refractive index of 1.55 at 35 °C, an optic diameter of 6 mm and an overall length of 13 mm. The lens is available in spherical powers ranging from +10.0 to +30.0 diopters.

  • DeviceBilateral implantation of LuxSmart™

    Patients will be implanted with LuxSmart™ during catarct surgery. The LuxSmart™ intraocular lens is a single-piece, acrylic hydrophobic and aspheric IOL with an overall diameter of 11 mm, an optical diameter of 6 mm, and a 4-point fixation haptic design. This non-diffractive IOL utilizes a technology known as Pure Refractive Optics (PRO), incorporating a 2.0 mm central EDOF zone that combines fourth- and sixth-order spherical aberrations of opposite signs designed to improve perceived depth of focus. The paracentral region, on the other hand, is a transition zone meant to gradually decrease the optic vergence from the center to the monofocal periphery. It has also a 360° continuous square edge on the posterior surface to prevent epithelial lens cells migration and posterior capsule opacification.

  • DeviceBilateral implantation of Eyecryl SERT

    Patients will be implanted with Eyecryl SERT during catarct surgery. EyeCryl-SERT (Biotech) is a new advanced monofocal, single-piece hydrophobic IOL with an aspheric surface, continuous vision from distance to intermediate, spectacle independence for intermediate vision, an extended range of vision: \>1.75 D at spectacle plane with visual acuity 0.2 LogMAR or better, an intermediate vision up to 57 cm and a design for fast neural adaptation.

  • DeviceBilateral implantation of RayOne EMV

    Patients will be implanted with RayOne EMV during catarct surgery. RayOne EMV (Rayner) is a new EDOF lens that has recently emerged in the market. It is a truly non-diffractive, single-piece hydrophilic IOL which does not use light splitting technology like many IOLs which increase depth of focus, resulting in low levels of dysphotopsia, similar to standard monofocal lenses. RayOne EMV is the only patented aspheric IOL that induces controlled positive spherical aberration. Compared to a lens with zero spherical aberration, the carefully controlled positive spherical aberration induced by RayOne EMV spreads light along the visual axis, elongating the focal range from far into intermediate with up to 1.5 D of depth of focus (per lens on the spectacle plane).

06

What researchers measure

Primary outcomes

  1. Distance-Corrected Intermediate Visual Acuity at 80cm (Unit: LogMAR)

    Monocular and binocular measurements of distance-corrected intermediate visual acuity (DCIVA) at 80cm in LogMAR.

    Time frame: From enrollment to the end of 3-month follow-up

  2. Distance-Corrected Intermediate Visual Acuity at 60cm (Unit: LogMAR)

    Monocular and binocular measurements of distance-corrected intermediate visual acuity (DCIVA) at 60cm in LogMAR.

    Time frame: From enrollment to the end of 3-month follow-up

  3. Binocular Defocus Curve (Unit: LogMAR)

    Following subjective refraction and determination of BCDVA, binocular defocus curve testing will be performed to evaluate the visual performance by adding defocus lenses from + 1.50 D to - 2.50 D in a randomized order.

    Time frame: From enrollment to the end of 3-month follow-up

  4. BInocular depth of Focus at 0.1 LogMAR threshold (Unit: Diopters)

    In order to comply with the recommendations of the American National Standards Institute (ANSI) Z80.35-2018 guideline regarding the definition of the EDOF IOLs, the binocular depth of focus will be calculated from the binocular defocus curve at 0.1 LogMAR threshold.

    Time frame: From enrollment to the end of 3-month follow-up

  5. Binocular Contrast Sensitivity Function (Unit: Log units)

    Using the Functional Vision Analyzer (Optec 6500, Stereo Optical Co., Chicago, IL, USA) across five spatial frequencies (1.5, 3.0, 6.0, 12.0, and 18.0 cycles per degree) under three standardized lighting conditions (photopic, mesopic, mesopic with glare).

    Time frame: From enrollment to the end of the 3-month follow-up

  6. Vision-related quality of life (Unit: Points on 0-100 scale)

    Using the validated Visual Function Index-14 (VF-14) questionnaire.

    Time frame: From enrollment to the end of 3-month follow-up

  7. Visual symptoms and their impact on daily life (Unit: QoV score 0-100)

    Using the validated McAlinden's Quality of Vision questionnaire.

    Time frame: From enrollment to the end of 3-month follow-up

Secondary outcomes

  1. Corrected distance visual acuity in LogMAR

    Corrected distance visual acuity at 4 m under photopic conditions (approximately 85 cd/m²) in LogMAR.

    Time frame: From enrollment to the end of 3-month follow-up

  2. Distance-corrected near visual acuity in LogMAR

    Distance-corrected near visual acuity (DCNVA) at 40 centimeters in LogMAR.

    Time frame: From enrollment to the end of 3-month follow-up

  3. Endothelial cell density, cells/mm²

    Specular microscopy to measure the endothelial cell density before and after the surgery.

    Time frame: From enrollment to the end of 3-month follow-up

  4. Safety outcomes

    The device-related serious adverse events will be reported.

    Time frame: From enrollment to the end of 3-month follow-up

  5. The development of posterior capsule opacification (PCO) on a scale

    The development of posterior capsule opacification (PCO) and the need for Nd:YAG capsulotomy will be reported as follows: 1. No PCO. 2. Peripheral PCO - clinically non-significant. 3. Clinically significant PCO (affect the visual acuity). 4. Clinically significant PCO that requires ND:YAG laser capsulotomy.

    Time frame: From enrollment to the end of 3-month follow-up

07

Study locations

1 of 1 sites recruiting
  • Augenklinik Ahaus
    Ahaus, North Rhine-Westphalia 48683, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Oct 2025, 42 months after the start.

Of 304 non-industry interventional studies with no phase under Cataract, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 42 months is above that.

Counting every sponsor, half of 494 studies reached it within 17 months; a quarter within 9 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2025
First posted
Jul 4, 2025
StartActual
Apr 12, 2022
Primary completionEst.
Oct 2025
CompletionEst.
Jan 2026
Last update
Jul 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07051720
Lead sponsor
Augenklinik Ahaus G + H GmbH & Co. KG
Responsible party
Matthias Gerl (CEO, Augenklinik Ahaus G + H GmbH & Co. KG) — Principal investigator
First posted
Jul 4, 2025
Start date
Apr 12, 2022
Primary completion
Oct 2025 (estimated)
Completion
Jan 2026 (estimated)
Last update
Jul 4, 2025

Study contacts

dr. med. (Univ. Bud.) Matthias Gerl, MD
Contact
m.gerl@augenklinik.de
+49 (2561) 9555-301
Matthias Müller, Dipl.-Ing.FH
Contact
M.Mueller@augenklinik.de
+49 (0)2561-9555-247
Labib Alshaweesh, MD, MSc
study director · Augenklinik Ahaus
Matthias Müller, Dipl.-Ing.FH
study director · Augenklinik Ahaus
dr. med. (Univ. Bud.) Matthias Gerl, MD
principal investigator · Augenklinik Ahaus

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion